In 2017,Tian, Junjun; Vandermosten, Leen; Peigneur, Steve; Moreels, Lien; Rozenski, Jef; Tytgat, Jan; Herdewijn, Piet; Van den Steen, Philippe E.; De Jonghe, Steven published 《Astemizole analogues with reduced hERG inhibition as potent antimalarial compounds》.Bioorganic & Medicinal Chemistry published the findings.Quality Control of 2-Chloro-1H-benzo[d]imidazole The information in the text is summarized as follows:
Astemizole is a H1-antagonist endowed with antimalarial activity, but has hERG liabilities. Systematic structural modifications of astemizole led to the discovery of analogs that display very potent activity as inhibitors of the growth of the Plasmodium parasite, but show a decreased hERG inhibition, when compared to astemizole. These compounds can be used as starting point for the development of a new class of antimalarials.2-Chloro-1H-benzo[d]imidazole(cas: 4857-06-1Quality Control of 2-Chloro-1H-benzo[d]imidazole) was used in this study.
2-Chloro-1H-benzo[d]imidazole(cas: 4857-06-1) binds to monoclonal antibodies, inhibiting their binding to their corresponding antigens. This activity may be due to its ability to bind covalently with amino groups on proteins and other molecules.Quality Control of 2-Chloro-1H-benzo[d]imidazole
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem